Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Cash: 2020-2025

Historic Change in Cash for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $21.8 million.

  • GeneDx Holdings' Change in Cash rose 1101.76% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 229.49%. This contributed to the annual value of -$14.5 million for FY2024, which is 61.56% up from last year.
  • GeneDx Holdings' Change in Cash amounted to $21.8 million in Q3 2025, which was up 185.40% from -$25.6 million recorded in Q2 2025.
  • GeneDx Holdings' Change in Cash's 5-year high stood at $424.8 million during Q3 2021, with a 5-year trough of -$93.3 million in Q3 2022.
  • In the last 3 years, GeneDx Holdings' Change in Cash had a median value of $1.8 million in 2024 and averaged -$3.8 million.
  • Over the last 5 years, GeneDx Holdings' Change in Cash had its largest YoY gain of 37,167.97% in 2021, and its largest YoY loss of 5,645.63% in 2021.
  • GeneDx Holdings' Change in Cash (Quarterly) stood at -$60.7 million in 2021, then dropped by 11.07% to -$67.4 million in 2022, then spiked by 118.36% to $12.4 million in 2023, then skyrocketed by 120.67% to $27.3 million in 2024, then surged by 1,101.76% to $21.8 million in 2025.
  • Its Change in Cash stands at $21.8 million for Q3 2025, versus -$25.6 million for Q2 2025 and $14.5 million for Q1 2025.